InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,288.80
(
-0.62%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.89
(
-0.14%
)
Bitcoin
64,612.58
(
-0.32%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: jaybe post# 32374

Thursday, 07/18/2013 10:14:37 PM

Thursday, July 18, 2013 10:14:37 PM

Post# of 80490
This study makes EGFR/FGFR combo even more clear....

Missed this one from March 2013.

http://www.nature.com/oncsis/journal/v2/n3/full/oncsis20134a.html

"...we suggest that treatment with combinations of EGFR and FGFR inhibitors may be superior to sequential treatment with an FGFR inhibitor."


Keep an eye on this Phase 1 trial by Novartis/ Genentech(Roche)combining gefitinib and dovitinib, results by end of year.

http://clinicaltrials.gov/show/NCT01515969
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up